We value all of the feedback left by our members and we want to say THANK YOU for all of your lovely comments!
To receive your information pack, become a member here
NICE recommends life changing technology is rolled out to people with type 1 diabetes
An announcement of the recommendations was made on 7 November 2023 at NICE’s annual conference in Manchester by NICE chief executive Dr Sam Roberts.
Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.
15-16 November 2023
Olympia London
diabetesprofessionalcare.com
Join us at Diabetes Professional Care on 15-16 November 2023 at Olympia London, the UK’s leading conference and exhibition for the entire team involved in the prevention, treatment and management of diabetes and its related conditions.
This new booklet is designed to help you through some of the confusing and complicated aspects of diet and the reasons why, what, and how much we eat are so important for people with Type 1 or Type 2 diabetes. It provides you with information about various diets, food labelling, weight loss, the importance of food groups and much more.
Semaglutide for early onset Type 1 diabetes – but a very small study…
In a small study involving only 10 people, semaglutide, a Type 2 drug, was given to people with Type 1 diabetes soon after the diagnosis. This led to no need for mealtime insulin in all patients and no need for basal insulin in most, along with improved glycaemic control. (The New England Journal of Medicine. September 2023)
Before building up our hopes, we have to recognise that this is a very small study and a much larger study is needed. In addition, we have to question whether there could be adverse effects.
NHS Press Release, 29th August 2023
UK Stakeholder | Press Releases | NHS England | 29 August 2023
Tens of thousands of people in England living with early onset type 2 diabetes will benefit from more intensive and targeted care, thanks to a world-first initiative being rolled out by the NHS.
Around 140,000 people aged 18 to 39 years old will receive additional tailored health checks from healthcare staff, and support with diabetes management, such as blood sugar level control, weight management and cardiovascular risk minimisation.
Department of Health and Social Care (DHSC) has issued a medicine supply notification for Tresiba Flextouch 100units/ml solution for injection 3ml pre-filled pens
Information is available on website: Medicine Supply Notification: Tresiba (insulin degludec) FlexTouch – Community Pharmacy England (cpe.org.uk)
On 9th May 2023, the Government and NHS announced an overhaul of primary care across England with the aim of making it easier for patients to contact their GP and end the 8am rush.
The deepening crisis in Ukraine means that there is an increasingly desperate need to help people trying to live with diabetes. It is hard to believe that not only are the people of Ukraine having to fight for their country and freedom, but they also are in desperate need all their diabetes supplies. As the bombing continues, pharmacies close, hospitals run out of supplies and supply routes targeted.
Abbott has recently identified that certain FreeStyle Libre 2 sensors from lot KTP005061 may provide erroneously high glucose readings. For example, your sensor glucose reading may be high and out of your target range while your actual glucose levels may be below or within target range.
NHS patients in England with Type 1 diabetes are now eligible for a free continuous glucose monitor (CGM) after the health service secured a new ‘cost-effective’ deal.
Earlier this year, the NHS announced it would rollout CGM technology to everyone living with Type 1 diabetes as part of its ‘Long Term Plan’ to deliver world-class healthcare. Now a deal between the NHS and manufacturer DEXCOM means a CGM called the Dexcom ONE Real Time-Continuous Glucose Monitoring will soon be available on prescription to people with Type 1 diabetes.
More than 250,000 people living with type 1 diabetes are set to be offered new technology to help them manage their condition and at the same time reduce the need for finger prick testing by up to 50%, following new advice from NICE. New guidance from NICE has recommended the use of real-time continuous glucose monitoring (rtCGM) for adults and children living with type 1 diabetes for the first time. It will give them a continuous stream of real-time information on a smartphone about their current blood glucose level.
Tetris Pharma has announced that people living with diabetes in the UK now have access to Ogluo® (glucagon Pre-Filled Pen). This is the first ready-to-use, pre-mixed and pre-measured liquid glucagon injection to treat severe hypoglycaemia in adults, adolescents, and children aged two years and over.
An article in The New York Times on December 3rd made headlines that are especially important for people living with Type 1 diabetes. It announced that Brian Shelton from Ohio had been cured of Type 1 diabetes. Curing Type 1 requires a renewable source of beta cells that can be produced in the laboratory. Once placed into the body, they need to restore insulin production and automatically regulate blood-glucose levels.
IDDT’s Chief Executive, Martin Hirst, has written an article for this week’s Diabetes Times, regarding the level of misleading information and terminology regarding diabetes, freely available on the internet.
This was a headline in November 2021 along with the statement that “Misdiagnosed Type 1 diabetes patients could be freed from the need to take insulin after a new test is rolled out.”
Scotland will become the first country to offer the C-peptide blood test to all patients who have had a Type 1 diagnosis for at least three years. The test became available from 1st November 2021 in Scotland.
Novo Nordisk has launched the PenCycle scheme to enable people to recycle their pre-filled FlexPen and FlexTouch devices by returning them to participating pharmacies or through pre-paid Royal Mail boxes which hold up to 12 used pens (with the needles removed).
This system, called PenCycle, started on 1st November 2021 and is being run in partnership with Alliance Healthcare, Lloyds Pharmacy, the National Pharmacy Association (NPA) and Royal Mail. It will be piloted in 13 clinical commissioning groups in Greater Manchester and Leicestershire and Rutland and in the Greater Glasgow and Clyde health board, ahead of a planned national rollout in 2022. The scheme is thought to be the first of its kind in the UK.
The DVLA has updated the guidance on glucose testing prior to driving. This now permits the use of interstitial glucose readings eg using Flash Glucose Scanning (FreeStyle Libre) and Continuous Glucose Monitoring (CGM) systems for Group 1 drivers only. However, finger-prick tests are still required (even for Group 1 drivers) under certain circumstances.